Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer?: Commentary

Nature Clinical Practice Oncology

Volumn 2, Issue 9, 2005, Pages 444-445

  Steensma, David P ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anemia; Cancer; Erythropoietin; Survival

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; SOLID TUMOR; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 27944501745     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0283     Document Type: Short Survey

References (4)

1. Littlewood TJ et al. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874
2. Leyland-Jones B; BEST Investigators and Study Group (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology 4: 459-460
3. Henke M et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260
4. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee. Minutes of the Meeting of Tuesday, May 4, 2004. [http://www.fda.gov/OHRMS/DOCKETS/ac/04/transcripts/4037T2.DOC] (Accessed 24 June 2005)